Tatva Chintan Pharma Chem · NSE: TATVA · BSE: 543321
Q2 FY27 results · Jul–Sep 2026
Tatva Chintan Pharma Chem reported revenue from operations of ₹217.32 crore (up 75.9% from Q2 FY26) and net profit of ₹21.45 crore (up 116.3% from Q2 FY26) for Q2 FY27 (Jul–Sep 2026), on a consolidated basis.
| Item | Q2 FY27 | Q2 FY26 | YoY | Q1 FY27 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 217.32 | 123.52 | +75.9% | 167.06 | +30.1% |
| Other income | 1.75 | 1.01 | +74.0% | 2.78 | −36.9% |
| Total income | 219.07 | 124.52 | +75.9% | 169.84 | +29.0% |
| Profit before tax | 28.94 | 13.66 | +111.8% | 21.11 | +37.1% |
| Net profit for the period | 21.45 | 9.92 | +116.3% | 15.98 | +34.2% |
| EPS, basic (₹) | 9.17 | 4.24 | +116.3% | 6.83 | +34.3% |
| Net margin (%) | 9.9 | 8.0 | 9.6 |
| Item | Q2 FY27 | Q2 FY26 | YoY | Q1 FY27 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 207.48 | 115.86 | +79.1% | 146.70 | +41.4% |
| Other income | 2.71 | 0.79 | +240.7% | 4.03 | −32.9% |
| Total income | 210.19 | 116.66 | +80.2% | 150.74 | +39.4% |
| Profit before tax | 20.44 | 12.34 | +65.6% | 14.09 | +45.0% |
| Net profit for the period | 15.39 | 8.94 | +72.1% | 10.45 | +47.3% |
| EPS, basic (₹) | 6.57 | 3.82 | +72.0% | 4.47 | +47.0% |
| Net margin (%) | 7.4 | 7.7 | 7.1 |
Consolidated
- Filed with BSE
- 19 Oct 2026, 18:10 IST
- Board meeting
- 19 Oct 2026
- Period
- 01 Jul 2026 to 30 Sep 2026
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 19 Oct 2026, 18:10 IST
- Board meeting
- 19 Oct 2026
- Period
- 01 Jul 2026 to 30 Sep 2026
- Review status
- Unaudited
- Source
- XBRL filing on BSE